超碰97人人射妻,日韩欧美在线综合网,精品国产亚洲一区二区三区,欲妇荡岳丰满少妇A片24小时

<pre id="2hm8k"><div id="2hm8k"></div></pre>

NKF's subsidiary Kindos's Etoposide Injection gets FDA approval for marketing

Continue to effectively leverage the advantages of the high-standard quality system and the integrated platform

2025-08-04

Learn more +
NKF makes its debut at CPHI Southeast Asia

It has opened up new channels for the company to penetrate the Southeast Asian and even the global market

2025-07-21

Learn more +
King-Friend will meet you in CPHI Malaysia！

Explore the infinite possibilities of the pharmaceutical industry!

2025-07-14

Learn more +
NKF's subsidiary Kindos's Hydralazine Hydrochloride Injection gets FDA approval for marketing

Strengthen and expand the international base of high-quality injectables

2025-06-09

Learn more +
NKF's subsidiary Kindos's Idarubicin Hydrochloride Injection gets FDA approval for marketing

Continue to promote high-quality products and services to a new level

2025-05-26

Learn more +
NKF's subsidiary Kindos's Mitoxantrone Injection gets FDA approval for marketing

Another quick approval

2025-05-22

Learn more +
Paclitaxel For Injection (Albumin Bound) approved by US FDA

2025-05-20

Learn more +
King-Friend will meet you in CPHI Frankfurt!

Explore the infinite possibilities of the pharmaceutical industry！

2025-05-19

Learn more +
King-Friend will meet you in CPHI Shanghai!

Explore the infinite possibilities of the pharmaceutical industry！

2025-05-13

Learn more +

1
2
3

Stock price

11.430

-0.040000000000001

?2025 Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd蘇ICP備13012010號

<source id="nnsq0"><ins id="nnsq0"></ins></source>